medrogestone and Ovarian-Neoplasms

medrogestone has been researched along with Ovarian-Neoplasms* in 3 studies

Trials

1 trial(s) available for medrogestone and Ovarian-Neoplasms

ArticleYear
Evaluation of 6,17 alpha-dimethyl-6-dehydroprogesterone for treatment of recurrent and metastatic gynecologic malignancy.
    American journal of obstetrics and gynecology, 1974, Feb-15, Volume: 118, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Medrogestone; Middle Aged; Neoplasm Metastasis; Ovarian Neoplasms; Parity; Pregnadienes; Progesterone; Progestins; Recurrence; Sarcoma; Uterine Cervical Neoplasms; Uterine Neoplasms

1974

Other Studies

2 other study(ies) available for medrogestone and Ovarian-Neoplasms

ArticleYear
[Comparison of the results of radio gold therapy, cobalt 60 teletherapy and chemotherapy in 330 ovarian neoplasms].
    Strahlentherapie, 1975, Volume: 150, Issue:3

    From 1960 to 1972, 276 out of 330 cases of ovarian cancer were treated by different techniques of postoperative radiation therapy; 54 advanced cases underwent prospective chemotherapy. Radiogold intraabdominally administered (190 to 300 mCi), telecobalt (5000 rd) or the combination of radiogold and telecobalt was chosen for postoperative radiation therapy. Cyclophosphamide (Endoxan), prednisolone, and gestagenes (Prothil) were given as a long-term chemotherapy. The most successful technique of radiation therapy is confronted with long-term chemotherapy after three years (five years) of survival: Stage I a, b, c: Radiogold = 91.7% (66.7%), chemotherapy (only I c) = 100%. Stage II a, b: Radiogold + telecobalt = 47% (35%), chemotherapy = 85%. Stage III: Radiogold + telecobalt = 25% (0%), chemotherapy = 52%. Stage IV: Radiotherapy = 0%, chemotherapy = 25%. The absolute five-year survival without chemotherapy amounted to 23%. The mortality curve under chemotherapy shows a four-year survival rate of 88%, if tumor cells had been detected microscopically (ascites, omentum), but of only 30% after macroscopical verification of the tumor. Therefore, the maximally possible partial resection of the tumor is recommended in inoperable stages before the beginning of chemotherapy. "Prophylactic" long-term chemotherapy following macroscopically complete surgical treatment is recommended, whenever microscopical spread of tumor cells appears to be possible. In inoperable stages, chemotherapy ought to be applied prior to radiation therapy. In stages I a, b, c, and II a, postoperative irradiation with radiogold (100 mCi) and in stage II b additionally radiation teletherapy of the pelvis (6000 rd) is recommended.

    Topics: Cobalt Radioisotopes; Cyclophosphamide; Drug Therapy, Combination; Female; Gold Radioisotopes; Humans; Medrogestone; Ovarian Neoplasms; Prednisolone

1975
6-Dehydro-6,17 alpha-dimethylprogesterone (NSC-123018) for the treatment of metastatic and recurrent ovarian carcinoma.
    Cancer chemotherapy reports, 1973, Volume: 57, Issue:2

    Topics: Adult; Diabetes Complications; Female; Humans; Medrogestone; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pregnadienes; Progestins

1973